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 Introduction 
 Erythema migrans (EM) is the hallmark of Lyme bor-
reliosis. The typical primary EM is a ring-shaped or ho-
mogeneous erythematous and usually peripherally ex-
panding skin lesion caused by  Borrelia burgdorferi  sensu 
lato  [1, 2] . In Europe  [1, 3–6  ] and in the USA  [7–9] , the 
median or mean maximum diameter of the primary EM 
varies between 10 and 20 cm with a range of 1–85 cm. 
 EM lesions with a size of less than 5 cm had previ-
ously been noted  [1, 3–9] . This is not in agreement with 
the US case defi nition stating that an EM should have a 
size of at least 5 cm  [10] . In Europe, a case defi nition al-
lows for the diagnosis of an EM if its size is less than
5 cm  [11] , but diagnostic criteria for such small lesions 
have not been discussed. In another European study, 
however, the isolation of  B. burgdorferi  sensu lato from 3 
EM lesions with a size of 2–4 cm has been reported  [1] . 
In this study, we present more details about the clinical 
and laboratory investigations of our patients with what 
we call mini EM. 
 Patients and Methods 
 Defi nition and Diagnosis 
 We defi ned a mini EM to be a cutaneous erythema with a max-
imum diameter of 2 up to less than 5 cm, remaining smaller than 
5 cm and being due to  B. burgdorferi  sensu  lato . The essential cri-
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 Abstract 
 Background: An erythema migrans (EM) remaining 
smaller than 5 cm in diameter, called mini EM by us, has 
not been addressed in detail.  Objective: To study the sig-
nifi cance of the mini EM as a sign of Lyme borreliosis. 
 Methods: Patients with suspected mini EM were retro-
spectively selected out of 257 consecutive patients with 
EM. The diagnosis of mini EM rested on the cultivation 
of  Borrelia burgdorferi. Species and subtype analysis of 
culture isolates was performed using outer surface pro-
tein A (OspA) polymerase chain reaction followed by re-
striction fragment length polymorphism and sequencing 
of the OspA gene.  Results: There was one patient with 
defi nite (0.4%) and another patient with a questionable 
mini EM.  Borrelia garinii OspA type 6 was identifi ed in 
the patient with the defi nite and  B. burgdorferi  sensu  lato 
in the patient with the questionable mini EM.  Conclusion: 
The mini EM represents an important and apparently 
uncommon sign of early Lyme borreliosis. 
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terion for the diagnosis of the mini EM was the identifi cation of
 B.  burgdorferi  senso lato  by culture and/or PCR within the ery-
thema. 
 Patients, Study Design, Follow-Up and Treatment 
 We carried out a retrospective study of 257 consecutive patients 
with the objective to study patients with mini EM in more detail. 
The 257 patients came from several German dermatological cen-
ters in which they were seen between 1978 and 1991  [3, 4, 12–14] . 
After the fi rst visit, the patients were usually followed for 3–12 
months, sometimes for years. All patients with established EM re-
ceived systemic antibiotic treatment  [4, 12–15] . 
 Cultivation and Subtype Analysis of B. burgdorferi sensu lato 
 Up to 1991, an attempt had been made to culture borreliae from 
fresh biopsy material of the suspected mini EM lesions in the labo-
ratory of Prof. Vera Preac-Mursic  [16, 17] . 
 In 2003, the  Borrelia isolates from patient 1 and from a patient 
with a typical expanding EM could be re-cultivated and subjected 
to subtype analysis using outer surface protein A (OspA) PCR with 
subsequent analysis by sequencing  [18] and restriction fragment 
length polymorphism  [19] of the amplicons. 
 Serology 
 The sera of our patients were tested for the presence of IgM and 
IgG antibodies against  B. burgdorferi by ELISA according to Wilske 
et al.  [20] and by immunoblot according to Schulte-Spechtel et al. 
 [21] . 
 Results 
 Patients with a Small EM at the First Visit 
 Five patients (2%) had a small EM with a size of less 
than 5 cm at the fi rst visit. Three of these patients (1.2%) 
developed typical ring-shaped peripherally expanding 
EM lesions with a size of 10, 20 and 21 cm in diameter, 
respectively, within the next 4 weeks. 
 B. afzelii was identifi ed in 1 of these 3 patients. 
 Patients with Mini EM 
 The remaining 2 patients were found to have a defi nite 
(patient 1) and a questionable (patient 2) mini EM. The 
erythema in these patients was bright red, homogeneous, 
nonindurated, nonraised and nonscaling. From both 
mini EM lesions,  B. burgdorferi  sensu lato could be culti-
vated. Species and subtype analysis from the isolate of 
patient 1 yielded  B. garinii OspA type 6. The isolate of 
patient 2 could not be re-cultivated for typing. None of 
the patients with mini EM had elevated antibody titers 
against  B. burgdorferi (confi rmed by repeated serological 
testing performed in 2002). 
 Case Report of the Patient with Defi nite Mini EM. 
Patient 1, a 26-year old woman, presented with an asymp-
tomatic erythema with a size of 2 by 2.5 cm at the fi rst 
visit. She had observed the lesion on the left thigh for 1 
week. A tick bite had not been noted. She complained of 
fatigue and abdominal pain. A biopsy from the erythema 
to culture borreliae was done at the fi rst visit. The lesion 
did not change in size until it subsided spontaneously 6 
weeks after the fi rst visit. The patient was seen by one of 
us (K.W.) at the fi rst visit and after 2, 4 and 7 weeks. At 
the follow-up after 7 weeks, she received amoxicillin 
500 mg with clavulanic acid 3 times daily for 2 weeks be-
cause the culture had revealed growth of  B. burgdorferi 
 sensu lato. Fatigue and abdominal pain subsided within 
a few weeks after therapy. There were no signs and symp-
toms related to Lyme borreliosis during the next 12 
months. 
 Fig. 1. EM of 3 days’ duration on the right lower leg, 2.5  ! 4 cm 
in diameter, in patient 2; from Weber et al.  [1 , colorplate I].
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 Case Report of the Patient with Questionable Mini EM. 
 Patient 2, a 43-year old man, presented with an asymp-
tomatic erythema with a size of 2.5 by 4 cm at the fi rst 
visit. The lesion had been noted on the right lower leg for 
3 days ( fi g. 1 ). A tick bite had not been observed. He suf-
fered from fatigue. A biopsy from the erythema to culture 
borreliae was performed 4 days after the fi rst visit. The 
patient decided to start taking doxycycline 200 mg daily 
for 2 weeks after the second visit although at that time 
the result of the culture was not yet available. As ascer-
tained by his wife, a physician, several times during the 
3-week period and by one of us (K.W.) after 2 weeks, the 
EM did not change in size until it disappeared within 2 
weeks after therapy. The fatigue subsided within a few 
days of therapy. Follow-up for 3 more years showed that 
he developed no later signs or symptoms related to Lyme 
borreliosis. 
 Discussion 
 Our observations on 257 consecutive patients have re-
vealed that a small EM with a size of less than 5 cm seen 
at the fi rst visit can develop into two directions. First, the 
small EM may peripherally expand into a typical EM. 
Secondly, the small EM may not reach a size of 5 cm in 
diameter at any time to represent a mini EM. 
 One of our patients with mini EM could be observed 
for 7 weeks without treatment. This time period appears 
to be suffi ciently long to assure that the patient did not 
develop a typical expanding EM. However, early antibi-
otic treatment could have prevented the development of 
a typical expanding EM in our patient 2 so that this case 
appears to be questionable. 
 EM lesions can strongly vary in size. The mini EM ap-
parently represents an EM which stops to expand after 
some time, expands so slowly or disappears so soon that 
it does not reach a size of 5 cm. The other extreme vari-
ant is an EM which spreads over large parts of the skin 
 [1–9] and rarely even over the entire skin within about 4 
months as reported in a single patient  [22] . 
 Early European Lyme borreliosis is occasionally asso-
ciated with another erythematous lesion which is usually 
smaller than 5 cm in diameter, borrelial lymphocytoma. 
However, borrelial lymphocytoma is a raised, indurated, 
tumor-like lesion preferentially occurring at certain sites 
such as the ear lobe or nipple  [23, 24] . 
 Contrary to a typical EM, a mini EM represents a con-
siderable diagnostic problem  [1, 25] . A couple of other 
dermatoses such as a nonspecifi c tick bite reaction, ec-
zema, granuloma anulare, tinea corporis, fi xed allergic 
drug reaction, the initial lesion of pityriasis rosea or ery-
sipelas might be considered. On the other side, an ery-
thema following a tick bite and not expanding to more 
than 1 cm in diameter most likely indicates a nonspecifi c 
tick bite reaction rather than a mini EM. 
 The diagnosis of a mini EM rests on the identifi cation 
of  B. burgdorferi sensu lato within lesional skin. In Eu-
rope, most EM lesions are now known to be associated 
with  B.  afzelii  [2, 6, 18, 25–28] . Yet,  B. garinii OspA type 
6 was identifi ed in one of our patients with  mini EM. 
This was somewhat surprising considering the recent 
fi ndings of Logar et al.  [6] , who obtained hints that EM 
lesions due to  B. garinii expand more rapidly than EM 
lesions due to  B. afzelii .  In their study however, the sub-
type (OspA type) has not been determined. For example, 
OspA type 4 is more often found among isolates from 
cerebrospinal fl uid than among isolates from ticks  [17] 
indicating differences of pathogenicity regarding differ-
ent OspA types of  B. garinii . Further work appears to be 
necessary to determine which species or subtype of  B. 
burgdorferi  sensu lato predominates in association with 
the mini EM. 
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